Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary
August 8, 2024
Earnings Call Speaker Segments
Diane Weiser
executiveHello, everyone, and thank you for being with us this afternoon. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Fady Malik, who leads R&D as EVP, will share news about SEQUOIA-HCM along with where things stand in the aficamten clinical trials program. Chris Murray, our SVP of Regulatory Affairs and Quality, will walk us through where we are following recent talks with FDA and EMA, plus how our planned regulatory filings are progressing. Andrew Callos, EVP and Chief Commercial Officer, will talk about what's underway on the commercial readiness front for aficamten. Updates on omecamtiv mecarbil, CK-586, and the earlier-stage development pipeline will come from Stuart Kupfer, SVP and Chief Medical Officer. Sung Lee, EVP and Chief Financial Officer, will take us through the financial picture for the second quarter and go over our revised financial guidance for 2024. Then, to close, Robert will discuss our corporate development strategies and walk through the milestones we expect ahead. A quick note: parts of what we say next, including answers to your questions, will cover future events and performance instead of historical facts, which makes them forward-looking statements. What actually happens could differ materially from what those forward-looking statements project. You can find more detail on the factors that might cause our actual results to differ materially from those in these forward-looking statements in our SEC filings, including the current report on our second quarter 2024 financial results furnished to the SEC today on Form 8-K. Following this call, we have no obligation to update any forward-looking statements. With that, I'll hand the call over to Robert.
Robert Blum
executiveThanks, Diane, and I appreciate everyone being on today's call. During Q2, we achieved meaningful headway and noteworthy milestones throughout our later-stage clinical development efforts, which rest on cardiac myosin modulation as their base, along with a considerable bolstering of our balance sheet and capital structure. That positions us to keep carrying out the possible commercial launch of aficamten and to keep pushing our pipeline forward. Back in May, we were delighted to share the primary results from SEQUOIA-HCM during a late-breaking clinical trial session at the European Society of Cardiology's Heart Failure 2024 Congress in Lisbon. As Fady will detail, those findings matched the high bar we had already set. The safety and efficacy profile for aficamten coming out of SEQUOIA-HCM indicates a potentially category-expanding chance as a next-in-class cardiac myosin inhibitor for HCM patients. Throughout the quarter, we kept up our conversations with FDA before our anticipated NDA submission. We took part in a productive Type B meeting with FDA to talk over possible approaches for safety monitoring and risk mitigation regarding aficamten. We feel good about how those talks proceeded, and we're proceeding according to plan. Chris Murray, SVP of Regulatory Affairs and Quality, is with us today to give an update on our regulatory interactions around the world. Turning to omecamtiv mecarbil, across the last 12 months, we ran many analyses of the GALACTIC-HF results. We engaged regulators multiple times, and we consulted heart failure experts about the unmet need and the potentially unique role omecamtiv mecarbil could have in treating heart failure patients, all while we weighed our possible next steps. What we discovered was a compelling chance for omecamtiv mecarbil to serve a large and growing population of people with severe heart failure who have few treatment options and face elevated hospitalization risk. Given the high adjacency to HCM when it comes to treating physicians, we think we can achieve a high return on investment by advancing omecamtiv mecarbil with minimal added commercial costs after aficamten's launch, and again, provided the confirmatory Phase III clinical trial of omecamtiv mecarbil produces positive results. Beyond that, together with CK-586, we see a synergistic opportunity from an R&D and commercial perspective to build a sustainable specialty cardiovascular franchise for patients and to further unlock and potentially maximize value for shareholders. All in all, we're proud to point to a broad development program for aficamten, with several potential label-expanding clinical trials underway, plus later-stage development programs in adjacent specialty cardiology indications, with more yet to come from our pioneering muscle biology research; we're establishing a specialty cardiology niche rooted in our myosin platform and aiming to improve patients' lives while also boosting shareholder value. With that, I'll hand the call to Fady, please.
Fady Malik
executiveAppreciate it, Robert. During Q2, we were delighted to share three late-breaking clinical trial presentations over in Lisbon. ... this included the primary results from SEQUOIA-HCM along with two further analyses drawn from that trial. Those primary findings, which came out at the same time in the New England Journal of Medicine, line up with our target product profile that could position aficamten as the cardiac myosin inhibitor physicians and patients pick first. The data showed that over a 24-week period, aficamten led to a meaningful improvement in exercise capacity—peak VO2 rose by 1.7 milliliters per kilogram per minute compared with placebo, and the p-value was 0.000002. That benefit was consistent in each pre-specified subgroup, including those taking beta blockers. All 10 secondary endpoints demonstrated improvements afterward, each with p < 0.001, and patients receiving aficamten had a substantial reduction in symptom burden, including a 7-point increase on the KCCQ and 34% of patients advancing by at least 1 NYHA functional class versus placebo. One additional way to evaluate aficamten's therapeutic benefit is to look at how it affects the hypercontractility that drives HCM. Within SEQUOIA-HCM, aficamten treatment brought about a notable and large decrease in the post-Valsalva LVOT gradient amounting to 50 mm Hg, which equals 60% of the baseline post-Valsalva LVOT gradient. Significantly, that drop in LVOT gradient came alongside an average LVEF reduction of under 5%. On the whole, we saw swift and sizeable declines in LVOT gradients with no adverse effect on left ventricular ejection fraction, matching an easing of the hypercontractility present in HCM. A newly published manuscript from Dr. Caroline Coats and colleagues in the Journal of the American Heart Association laid out the safety and dosing findings from SEQUOIA-HCM and broadened as well as strengthened these early observations. That paper gives a thorough account of the main SEQUOIA-HCM results that aligned with its aspirational pharmaceutical profile and were built into aficamten. To be specific, these analyses revealed that aficamten lowered LVOT gradients quickly, within two weeks of starting treatment, and did so without requiring any discontinuation or interruption of treatment through the dose escalation Phase. On top of that, pharmacokinetics proved generally linear with low variability after reaching the target dose, which produced minimal LVEF change throughout the maintenance Phase of treatment, basically no different from placebo on that measure. Down titration for LVEF under 50% proved effective, and the reversibility of its pharmacodynamics was shown convincingly. Crucially, no heart failure events were linked to it. In HCM, the aim of treatment isn't merely lowering the LVOT gradient; it's also to bring left ventricular ejection fraction to normal. As outlined in the paper, patients on aficamten whose LVEF excursions from baseline were largest — 20% or higher — every one of them started with baseline LVEFs above 75%. At no visit did any of these people have an LVEF under 50%. So the biggest LVEF reductions took place among participants whose hypercontractility was most severe, which fits the treatment's objective. At the European Society of Cardiology's forthcoming meeting in London, six presentations connected to aficamten will be given by us, among them four late breakers plus two oral presentations. We'll be sharing SEQUOIA-HCM data that covers KCCQ, cardiac structure, function, and biomarkers. We're also going to present an integrated safety analysis that comes out of FOREST-HCM, along with information about withdrawing standard of care medications. Our view is that when you put these presentations side by side, they'll substantially broaden the picture of how aficamten is performing relative to our target, target product profile. Now, on the ongoing clinical trials program for aficamten, we're pleased to report that MAPLE-HCM enrollment is still on track to finish during this quarter. As a matter of fact, we've stopped looking for additional patients to go into screening. Just to remind everyone, this study is looking at whether aficamten alone might be better than metoprolol alone for obstructive HCM. If we finish signing up patients during this quarter, we think that puts us on track to have data in the first half of 2025, which is sooner than the point when we're hoping to start selling aficamten commercially. Should the results come back positive, that could open the door to expanding the label and give us proof of how aficamten might serve as an initial treatment option versus beta blockers in guidelines used in actual practice. We've made a lot of headway with ACACIA-HCM, our pivotal Phase III trial of aficamten in people who have symptomatic non-obstructive HCM, and we're continuing to bring clinical sites online throughout this quarter. Patient sign-ups are coming in at a good pace and are still in line with what we've been projecting. Looking ahead across this year, our plan is to keep enrolling patients in ACACIA-HCM, with the goal of wrapping up enrollment during 2025. The European Journal of Heart Failure recently put out a brief report featuring findings from 34 nHCM patients who received 36 weeks of treatment in FOREST-HCM, our open-label extension study. This represents the earliest dataset we've gathered on longer-term aficamten treatment among nHCM patients. The drug was generally well tolerated, and those taking it showed meaningful gains in symptom burden, NYHA functional class, and NT-proBNP. There were no discontinuations linked to adverse events. These findings indicate that aficamten, when given over a longer period, may be both safe and effective for nHCM patients. We're eager to potentially expand upon this with additional data from FOREST-HCM, and naturally, to review what ACACIA-HCM shows once it's ready. Turning to CEDAR-HCM — that's the fourth trial of aficamten currently underway, and it focuses on a pediatric group with symptomatic OHCM; enrollment began there during the second quarter. Through CEDAR-HCM, we have a chance to broaden aficamten's possible use into another portion of the wider HCM population, which could help further define a next-in-class profile. Finally, in the quarter, we launched a Phase I trial assessing the pharmacokinetics, safety, and tolerability of aficamten in healthy Japanese and Caucasian volunteers, aiming to collect the data we think will be necessary for possible approval of aficamten in Japan. This again broadens the potential for aficamten to deliver a meaningful, positive, and differentiated effect on patients' lives. With that, I'd like to turn it over to Chris Murray, who will provide an update on aficamten from a regulatory perspective.
Chris Murray
executiveAppreciate that, Fady. It's good to be on the call today and walk everyone through where we stand on the regulatory front from this past quarter. Like Robert said, in advance of the NDA filing we intend to make for aficamten, we took part in a Type B meeting with the FDA over the quarter, and at that meeting we talked through approaches for monitoring safety and mitigating risk to back up that NDA submission. Just to remind everyone, we had wrapped up two prior meetings with the FDA back in February — one to go over the SEQUOIA-HCM results, and a second pre-NDA session covering particular topics tied to our filing. That latest third meeting gave us a valuable chance to go deeper on aficamten's safety and pharmaceutical characteristics and to talk about how those might shape ways of handling risk, plus to get a read on where the FDA stands on the issue; we feel really good about how things have gone across this set of meetings with the FDA, and about the FDA's ongoing engagement as we get ready to hand in the aficamten NDA. We recognize that mitigating risk will in the end be something the FDA reviews, but after the Type B meeting we just held, our plan is to put forward a risk mitigation strategy tailored specifically to aficamten alongside the NDA. One more key thing to come out of that Type B meeting: the agency signed off on amending the protocol for FOREST-HCM, our open label extension study that's still running, so that echo monitoring happens less often during the treatment maintenance Phase. Under that amendment, patients with OHCM can now have echo monitoring once every six months rather than once every three months while on maintenance treatment, provided their LVEF sits above 55% and no other conditions that could compromise systolic function are present. That protocol change rested on the safety and tolerability profile seen across the development program so far. As we've said before, no treatment interruptions tied to aficamten have shown up in FOREST-HCM up to now. The way echo monitoring is handled, as now put in place in FOREST-HCM, points to a possible real-world, risk-based method for clinicians managing patients on aficamten. As we shared previously, the FDA has agreed that we can submit the NDA on a rolling basis, which lets the FDA potentially start reviewing finished modules earlier. I'm glad to report today that we kicked off the first portion of that rolling submission in July, and we remain on track to wrap up the rolling submission during this third quarter. Beyond the work that puts us in position to file the NDA with the FDA this quarter, we're also still getting our MAA ready to submit to the European Medicines Agency. Over the quarter, we held pre-submission meetings with the EMA and with national agencies in the EU, and in those we confirmed our plan to file an MAA in the fourth quarter of this year, and we reached alignment on what the submission will contain. At the same time, we've taken part in pre-submission meetings that happened recently with China's Center for Drug Evaluation, and alongside our collaborator Ji Xing, we're working together on plans to file an NDA in China before this year is done. Taken together, Cytokinetics is making significant progress to secure aficamten submissions in the world's key regions. I'll now hand things over to Andrew.
Andrew Callos
executiveAppreciate it, Chris. During Q2, we wrapped up the market development campaign for aficamten, and we intend to kick that off at HFSA next month, while we keep shaping the full patient treatment experience — this covers our specialty pharmacy distribution approach along with the patient support program. Now that we have the SEQUOIA-HCM result in hand, we moved forward on multiple market research studies so we could gain a clearer picture of how the trial's findings affect our potential product positioning, value proposition, and market opportunity. What I've been seeing in recent preference share research is encouraging, and ultimately that work will be shaped by our label and our distinct risk mitigation approach. ... Throughout the quarter, we kept up our engagement with U.S. payers as well. Our payer account management team recently started pre-approval information exchange with key payers in order to walk through the SEQUOIA-HCM results and the economic burden of obstructive HCM, and we anticipate carrying on these interactions until our PDUFA date; on top of that, we kicked off development of a payer value dossier covering both the U.S. and Europe, which is meant to define the overall value proposition backing our planned reimbursement. In parallel, we worked on locking down plans regarding size, structure, and alignment of field-based sales teams, drawing on HCM diagnosis and treatment claims. As a reminder, our spending follows a disciplined, gated approach as we get ready to build out commercial infrastructure; right now we have in place a field sales leadership team that is nearly complete, though that accounts for only a small percentage of our overall sales infrastructure, and our intention is to bring on the full sales team during 2025, timed closely to when aficamten could potentially receive regulatory approval. We likewise kept making headway on European commercial planning work tied to positioning, branding, distribution, launch strategy, and reimbursement, with Germany as the first country where we would expect to launch aficamten, followed by other key European countries; we're keen to keep ramping up commercial readiness efforts over the course of this year and on into 2025. As a reminder, the goal is to keep constructing a specialty cardiology franchise, an area where we see substantial potential to compete and win. Rather than a broader cardiology approach, specialty cardiology involves interactions centered on a concentrated prescriber base within a subset of cardiologists, a limited distribution model, high-touch patient support services, and a sizable opportunity to address unmet patient need — all of which points toward the possibility of a high return on investment. We're making solid progress toward that future, which aficamten will lead; with that said, I'll hand the call over to Stuart.
Stuart Kupfer
executiveThank you, Andrew. Let me begin by discussing omecamtiv mecarbil. During our conversations with the FDA, the agency determined that findings from GALACTIC-HF on their own did not support an approval, but they did favor running another clinical study of omecamtiv mecarbil. As you may remember, GALACTIC-HF, the cardiovascular outcomes trial involving over 8,000 patients, showed a meaningful decrease in heart failure outcomes when omecamtiv mecarbil was added to standard of care, and that effect was twice as large in the sizable pre-specified subgroup of higher-risk individuals with reduced ejection fraction. Among patients with more recent heart failure hospitalizations, elevated NT-proBNP, and lower blood pressure, both heart failure risk and treatment benefit rose even more. Since the lower ejection fraction subgroup included more than 4,000 patients, we hold strong confidence in the potential advantage of omecamtiv mecarbil as an add-on to standard of care for those suffering from severe heart failure. Roughly 2,000 HFrEF patients with severe heart failure will be enrolled in the planned confirmatory Phase III trial, which will incorporate pragmatic design elements making it smaller and more efficient compared with GALACTIC-HF, such as less stringent safety monitoring requirements, a run-in period to enrich for more adherent patients, and simplified entry criteria. We're getting ready to launch this trial in Q4 of this year. Turning now to CK-586, our additional cardiac myosin inhibitor. Let me remind you that we laid out this mechanism in some detail at the 2023 biophysical meeting. We chose to optimize the lead series that yielded CK-586 since its mechanism of action differed from aficamten's. Unlike aficamten, CK-586 does not bind to the motor domain of myosin; rather, it binds to myosin's regulatory light chain and acts as a partial inhibitor of the myofibril ATPase. We continue to view CK-586 as a cardiac myosin inhibitor with a distinct mechanism of action of its own, and we're moving it forward into further clinical development for HFpEF. In the second quarter, we reported top-line data from the Phase I study, which demonstrated that CK-586 was safe and well-tolerated among healthy participants, with generally linear pharmacokinetics at single doses ranging from 10 to 600 mg. At the highest single dose of 600 milligrams, the mean reduction in LV ejection fraction relative to placebo came in under 5%. The PK/PD relationship for CK-586 looks even shallower than that of aficamten, and its half-life is shorter; we intend to share these data in full at a medical meeting this quarter, and since the top-line findings support moving the program ahead, we're preparing to initiate a Phase IIA clinical trial in Q4 of this year in patients with HFpEF. We're happy with CK-586's profile and think it could further strengthen our leadership in cardiac myosin modulation as well as our specialty cardiology franchise. Lastly, I'd like to give an update on CK-136. In Q2, we finished going through the results from the Phase I trial, and that trial achieved its main goal of evaluating the safety, tolerability, and pharmacokinetics of both single and multiple doses of CK-136 in healthy volunteers. No safety signals or adverse effects turned up in that Phase I study. That said, given the decision we made recently to move omecamtiv mecarbil forward, another sarcomere activator, and following our portfolio review committee's examination of the Phase I data along with other strategic priorities, we found no compelling opportunity for CK-136 compared with omecamtiv mecarbil. So because of that, we've chosen to stop developing CK-136 any further. With that, I'll hand things over to Sung.
Sung Lee
executiveThanks, Stuart. We are happy to share the financial results for our second quarter of 2024. Let's begin with the balance sheet. At the close of the second quarter of 2024, we held roughly $1.4 billion in cash, cash equivalents, and investments, which compares with $634.3 million at the conclusion of the first quarter of 2024. This sequential gain was mainly the result of completing a public offering of common stock during the second quarter, which generated net proceeds of $563.2 million once underwriting discounts and commissions were subtracted. Additionally, in May we signed a $575 million strategic financing agreement with Royalty Pharma, which provided $250 million at signing. That upfront sum consists of $100 million to fund a confirmatory Phase III clinical trial of omecamtiv mecarbil, a $50 million investment in a Phase IIA clinical trial of CK-586 in HFpEF, a $50 million term loan supporting the potential commercial launch of aficamten in obstructive HCM, and $50 million for shares of common stock in a private placement. The remaining $325 million consists of a term loan of up to $175 million that we may choose to draw once certain conditions are met, plus an investment of up to $150 million by Royalty Pharma in a Phase III clinical trial of CK-586, if Royalty Pharma decides to opt in to fund that trial in return for a higher revenue interest in CK-586. We view the overall financing package as carrying an appealing, market-competitive cost of capital, and together with the net proceeds from the equity financing, it puts us in a strong position to support the commercial launch of aficamten, broaden its development program, and move our pipeline forward. Turning to the income statement. Total revenues for the second quarter of 2024 came to $0.2 million, versus $0.9 million in the same period of 2023. R&D expenses for the second quarter of 2024 were $79.6 million, versus $83.2 million in the same period of 2023. That decline was mainly due to the timing of clinical trial activities and wind-down activities for COURAGE-ALS, which concluded in the first quarter of 2023. G&A expenses for the second quarter of 2024 were $50.8 million, versus $39.7 million in the same period of 2023. That rise was mainly due to investments toward commercial readiness and personnel expenses. Net loss for the second quarter of 2024 was $143.3 million, or $1.31 per share, basic and diluted, versus a net loss of $128.6 million, or $1.34 per share, basic and diluted, in the same period of 2023. Now I would like to discuss our updated financial guidance for 2024. We expect GAAP operating expenses to land between $555 million and $575 million, versus the prior range of $535 million-$555 million. Non-cash operating expense, made up of stock-based compensation and depreciation, which is included in GAAP operating expense, is now expected to land between $105 million-$110 million, versus the prior range of $105 million-$115 million. When you strip out stock-based compensation along with depreciation, our non-GAAP operating expenses should land somewhere in the range of $445 million to $470 million, which is up from the earlier guidance of $420 million to $450 million. On net cash utilization, the expectation now sits at $400 million to $420 million, versus the prior range of $390 million to $420 million. What's behind the higher GAAP and non-GAAP operating expenses is mainly the launches of the Phase IIA study for CK-586 and the Phase III study for omecamtiv mecarbil. Having said that, let me turn things back to Robert.
Robert Blum
executiveThanks, Sung. As Sung laid out, our financial standing is strong, and our capital structure has been reinforced — something we think will see us through a possible commercial launch of aficamten. It should also let us keep running possible global clinical trials of aficamten that could expand its label and the category, while simultaneously moving forward our later-stage development pipeline, which includes omecamtiv mecarbil and CK-586, all concentrated on a single area of biology within adjacent cardiology specialty segments. With that in mind, we recently restated our plans to push ahead with commercial strategies and to build out our specialty cardiology franchise. That said, as we noted in an 8-K filed during the second quarter, we likewise acknowledge our fiduciary duty to weigh every possible opportunity for maximizing shareholder value. That could mean growing the business in the manner we've described today, or it could mean M&A. We are fully aware of what we owe our shareholders, and we will evaluate alternatives. Still, the path we can ourselves take today toward maximizing shareholder value is to build lasting value in our pipeline and become a category leader with aficamten at the center... We also intend to draw on our R&D and financial strengths to bolster our pipeline through possible outside opportunities. Along those lines, this quarter we were happy to add a new face to our corporate steering committee, Isaak Ciechanover, joining as Executive Vice President, Corporate Development and Chief Business Officer. Before this, Isaak was CEO of Atara Biotherapeutics. He headed business development at Celgene and held partner roles at top venture capital firms. Isaak's remit covers growing the company's footprint in new geographies, sparking external R&D efforts, and charting possible new business objectives, which might encompass possible divestitures and spin-out companies, plus potentially M&A, on both the buy side and the sell side, and other business combinations. Isaak carries a deep well of knowledge and expertise, and we're thankful for that as we keep building Cytokinetics. Our achievements this past quarter make me proud, and as you've heard, we're particularly happy with how things progressed with FDA regarding the NDA submission for aficamten and its potential for a distinct risk mitigation profile, should it be approved for commercialization. But before we get to questions, I want to stress that because our discussions with FDA are proprietary and confidential, we don't intend to give further details about our meetings with FDA, and we don't plan to offer further updates on these matters, given that answers to any outstanding questions will hinge on FDA review. Now I'd like to sum up our upcoming milestones. On aficamten, we expect to share additional results from SEQUOIA-HCM at the European Society of Cardiology Congress later this month. We expect to file an NDA with the FDA in Q3 2024, an MAA with the EMA in Q4 2024, and to work with Ji Xing to support the planned NDA submission to the NMPA in China in the second half of this year. Regarding MAPLE-HCM, our expectation is that enrollment wraps up during the third quarter of 2024. Enrollment in ACACIA-HCM should keep going across 2024, and our goal is to finish it in 2025. CEDAR-HCM enrollment ought to carry on this year, the Phase I trial of aficamten involving Japanese and Caucasian participants should also proceed this year, and we anticipate pushing forward with our go-to-market plans for aficamten all year long; as for omecamtiv mecarbil, a confirmatory Phase III clinical trial is expected to begin in the fourth quarter of 2024. When it comes to CK-586, we plan to share primary data from the Phase I study at a medical meeting in this third quarter of 2024, and to launch a Phase IIA clinical trial in the fourth quarter of 2024. On the preclinical development and ongoing research side, we look to kick off clinical development with a fast skeletal muscle troponin activator later this year, while carrying on preclinical development and research work aimed at further muscle biology-focused programs for the rest of the year. Operator, that being said, let's now take questions on the call, please. Good afternoon, Salim.
Salim Syed
analystHello Robert, good afternoon. I appreciate you fielding this, and congratulations on the advancement. Also, I'd like to extend a welcome to Isaak as he joins the organization. My query relates directly to that topic—Isaak coming aboard. Could you perhaps share how you are approaching this strategically? From what I can tell, there wasn't an 8-K or any press release I saw, yet this appears significant for the business. So perhaps you could outline the expected rhythm of business development efforts, and most importantly, any refreshed perspective regarding aficamten. Is Europe a possibility, or was this primarily aimed at pursuing business development opportunities tied to omecamtiv mecarbil? Thanks.
Robert Blum
executiveSure. To be clear, our approach to aficamten remains unchanged, whether we're talking about Europe or North America. Furthermore, I'm confident that our existing business development work concerning aficamten in Japan is already progressing nicely. Bringing Isaak into the fold relates less to those items and more to what I'd categorize under corporate development rather than business development. I can see Isaak stepping up to lead as we evaluate which regions we may wish to expand our presence in, given that we operate as an ongoing R&D and commercial entity. Even more importantly, he'll help enhance our approach to muscle biology, covering both acquisition-side and possible divestiture-side endeavors. To clarify: as a pioneer and leader in this field, we believe we're positioned well... to envision fresh possibilities and opportunities, whether that means generating revenue from our current work or merging with prospective partners. As we've talked about before, and as numerous investors have inquired previously: What's our view on spinning out companies? What's our view on possibly becoming a technology aggregator? I wouldn't anticipate anything substantially large. For example, I don't see this affecting our spending plans in any major way, yet I do believe it connects to how we leverage our leadership position in this area and sustain that leadership going forward. I'm confident Isaak will serve as an excellent architect, collaborating with R&D teammates, on how that strategy eventually gets executed—not so much during this year, but increasingly in the years ahead. I trust that addresses your question.
Salim Syed
analystRight, that's correct. Many thanks.
Robert Blum
executiveGood afternoon, everyone.
Akash Tewari
analystHi there, good afternoon. I know you're not able to discuss your FDA meeting, but what conclusions should we draw from this protocol amendment for FOREST, which now permits a 6-month echo for patients whose LVEF is above 55? Wouldn't that be a strong signal of what a REMS will eventually look like? Also, could it be that the FDA decides no REMS is needed at all, while waiting on additional follow-up data from FOREST? And Robert, maybe I can squeeze in one more. You mentioned reasons you might spin off certain assets. What's the reasoning behind separating certain assets before potential mergers or acquisitions, especially when another company with a mixed bag of holdings might have some overlap? I'm particularly curious about CK-586 and the idea of divesting that one. Thanks.
Robert Blum
executiveYeah, so please don't read what I said before as some kind of signal that we're looking at spinning off programs in later-stage clinical development. Our view is that the specialty cardiology franchise is the way we get the most shareholder value — whether we do that independently or, as you raised, through possible M&A. That said, I think there's substantial worth in our preclinical work and other efforts as we move past specialty cardiology, and those could eventually be turned into money through different routes, and they could also gain from being financed in different ways. On your FDA question, once more, let me stress that discussing that meeting in more detail isn't really something I'm able to do. Even so, our view is that FOREST provides an actual-practice assessment of aficamten. And it makes us glad that the FDA shares our thinking: since we'd been tracking echoes more often within FOREST across an extended period, gathering a substantial volume of information that, clinically speaking, wasn't leading to any significant shifts in how these individuals receive care. The FDA appeared open to the suggestion we made about adjusting how often echo monitoring would need to take place. That's a positive sign. But in the end, I wouldn't go as far as drawing a straight line, the way you're asking, between that adjustment and whatever action the FDA might take regarding a possible risk mitigation profile. Linking those points together is something I'm not prepared to do during this call. Fady, is there anything else you'd like to say about that?
Fady Malik
executiveSo basically, when the FDA agreed to the amendment we submitted for FOREST, and as a result, the echocardiogram being done every 6 months — that really shows what the data we've produced so far looks like. So my expectation is that those same data will carry weight when they go through our NDA as well.
Analyst
analystHello, Mike here, sitting in for Jeff Hung. We appreciate you fielding our question. When we look at HCM and consider things more broadly, doctors probably know by now what CMIs can offer, yet adoption is still happening at a slower pace, and many of these individuals continue to arrive already on a beta blocker. So with that in mind, what's your take on the MAPLE data, and would that be the piece required to establish CMIs in the frontline setting and truly drive that wide and swift pickup? Thank you.
Robert Blum
executiveI'd like Fady to address that, please.
Fady Malik
executiveOkay, so that's a fair question. The main purpose behind creating and carrying out MAPLE, I'd say, was to generate support for aficamten being used as a first-line treatment — and not simply when it comes to easing symptoms and boosting function, which we're hoping to show head-to-head versus beta blockers. But beyond that, we're also examining how the heart remodels differently, and what happens with wall thickness. With long-term dosing of cardiac myosin inhibitors, there are certain observations we've made, yet nobody has truly described whether those same effects show up with beta blockers. Our view is that the data taken together would point not just to better function and fewer symptoms, but hopefully would also reveal signs of disease modification. So I believe all of that ought to eventually help shift the standard of care away from starting with a beta blocker toward a CMI.
Analyst
analystThanks so much.
Robert Blum
executive... Thanks.
Roanna Ruiz
analystHi there. Good afternoon, all. So I suppose, following up on what was said regarding MAPLE, I wanted to ask whether you might expand on that somewhat. It sounded as though you noted that it would be possible to draw on certain MAPLE data, or the early results, and give those to the FDA while the agency is going through its review of aficamten's filing. Might there be any effect on aficamten's potential label from that?
Fady Malik
executiveI'll handle that one, Roanna. What I believe I stated during my portion was that those data would be on hand before aficamten gets approved — not that we would definitely put them into our application, since that application will by then have been submitted and already moving along. Still, our expectation is that a publication of those data could come out near when aficamten might receive approval. And I think those data are quite compelling, and they will simply serve as one more reference point that physicians, along with our commercial team, can use to demonstrate what this mechanism of action can do.
Roanna Ruiz
analystUnderstood. Doctors could also look at this for reference, correct?
Fady Malik
executiveIndeed, assuming it ends up being published, they definitely will, since I anticipate that it will.
Roanna Ruiz
analystYep, fair enough. Thanks.
Robert Blum
executiveHey, Paul.
Paul Choi
analystHey, can you hear me?
Robert Blum
executiveYes.
Paul Choi
analystHello, and good afternoon. Thanks for taking our question. Robert and Fady, I'd like to hear your perspective on what comes next and how development is being planned for HFpEF as well as HFrEF, given the recent positive GLP-1 data. What are your thoughts on how that could serve as a potential treatment target within the algorithm or modality for heart failure? And also your thinking on planning trials for CK-586 and omecamtiv mecarbil going forward. Thank you very much for taking our question.
Robert Blum
executiveYeah, thanks for that question. Given what we see as complementary mechanistic work rooted in myosin modulation, I think it's a very important one. That work can offer an opportunity that would sit alongside other therapies, but also for patients who might not benefit in the same way from those other therapies. For that, I'll turn to Fady to elaborate.
Fady Malik
executiveSo, I mean, similar to a lot of concomitant medications, they initially address a particular group — a subset of patients who respond well to them. Clearly, their emphasis is on those with pronounced obesity. A great many HFpEF and HCM — or actually HFpEF and HFrEF — individuals aren't obese, and in their case, you really wouldn't anticipate seeing adoption of the GLP and GIP agonists. So my sense is it's largely about better defining who the patients are, so you're not dealing with, well, something of a shifting target. Ideally you'd avoid that — much as we handle other concomitant medications, we insist they remain stable on that background treatment prior to joining the study, and in the same way, a patient who wasn't considering starting a GLP-1 likely wouldn't qualify to stay in or to enroll in our study, at minimum until their weight had stabilized and they still went on to satisfy the eligibility criteria. So there are, you know, fairly routine approaches for managing that, which I believe we will definitely use.
Robert Blum
executiveAlright, perhaps I could just make one additional point. Although it's encouraging to observe certain of these advances in HFrEF and HFpEF, I believe analysts and investors sometimes fail to appreciate just how unacceptably elevated the remaining morbidity and mortality continue to be among these individuals, and particularly how many of them are still unable to tolerate standard of care. That's precisely where we think chances exist for myosin modulation in combination with those treatments. Consequently, we look forward to assessing omecamtiv as well as CK-586 in settings and in individuals who might not gain from these other approaches and mechanisms.
Robert Blum
executiveGood afternoon.
Kripa Devarakonda
analystGood afternoon, Robert. I really appreciate you taking the time for my question. So, based on what your slides show, it looks like CMI preference share for aficamten among the eligible patient population comes in at roughly 60%. What I'm curious about is whether patients might move from mavacamten over to aficamten, particularly if safety is a worry for them or they aren't happy with how well it works. That might not be what you're assuming as your base case, but I just wanted to ask whether, from your market survey or your survey of KOLs, you think that's something that could happen. Thank you.
Robert Blum
executiveYeah, you and other analysts have looked into that area, and we find the work compelling when it comes to possible switches, but as Andrew can now explain, and like you mentioned, that isn't central to our strategy. But Andrew, perhaps you'd like to address that?
Andrew Callos
executiveSure, absolutely. So I suppose there are a few points. First, we anticipate that the great majority of patients — likely more than 80% of the market — will be available and not receiving a CMI treatment at the time aficamten, you know, were it to gain approval. Second, our attention will be on new patients, teaching physicians about aficamten and what sets aficamten apart. What our research shows us is that this will likely grow the market, meaning additional patients, additional physicians and additional patients on a CMI, and it will grow share. We are not going to discuss switches. We are not going to pursue switches. Should patients be stable on mavacamten or any other product that works for them, then that decision will rest with the physician and the patient in that conversation, if they wish to make a switch.
Kripa Devarakonda
analystThank you so much.
Andrew Callos
executiveThank you.
Robert Blum
executiveHello there, Yasmeen.
Analyst
analystHi. Good afternoon to you as well, Robert. This is Jun Gwon sitting in for Yas. We appreciate you taking our question. Regarding omecamtiv mecarbil, might you share a bit more detail about which steps remain that are rate-limiting or gating before the study can kick off?
Robert Blum
executiveCertainly, and there aren't many. Fady and his team have been working extremely diligently to get everything ready so this study can begin, and I'll have him address those points in some depth.
Fady Malik
executiveI'll begin and ask Stuart to go into more detail, but the trial, basically, as we've said previously, we've had interactions with regulators. We've broadly reached agreement on the protocol, so what remains is setting up the trial's operational side. If you recall, we also rely on a plasma concentration assay that we need to stand up once more; so it's largely operational, and with that, I'll turn to Stuart to see if he has anything to add.
Stuart Kupfer
executiveTo build on that point, we're genuinely at a stage where we've gained substantial knowledge, naturally, from GALACTIC-HF; we possess this enormous database that guides us toward the right target population, refines the study design for this new trial even more, and assists us in basically conducting a study that is even more efficient while concentrating on a higher-risk population, which also results in a leaner trial. So I believe we're well positioned to begin in the fourth quarter.
Yasmeen Rahimi
analystAll right. Thank you very much.
Robert Blum
executiveThank you.
Robert Blum
executiveHi, Charles.
Charles Duncan
analystHello, Robert. Yes, hi, Robert, and hello to everyone on the team. Congratulations on the solid advancement and the meeting held recently with the agency. I had one brief question regarding enrollment in MAPLE. Yes, it appears that will wrap up before long. However, remarks from Fady pointed toward definitely expecting that to occur after approval, so I suppose what I'm asking is whether you might give us some additional detail about the timeline you foresee for reviewing afi. Are you working under the assumption of a fast review and approval, or could it be that the MAPLE data might be asked for or incorporated as part of the initial NDA?
Robert Blum
executiveIt's possible you misheard Fady's comment regarding timing, and what he meant was that we anticipate MAPLE results arriving before the point at which approval of aficamten might be expected. But Fady, would you like to add anything else?
Fady Malik
executiveYeah, and I believe during my prepared comments I mentioned that our expectation is for that in the first half of 2025. You can sort of calculate it yourself and figure out where within that first half it might fall. However, whether a priority review or a standard review is granted, that decision is still to come before any possible approval. So my expectation is that those data will become publicly available, though they won't necessarily be part of the filing. Also, I should mention that a safety update will occur while our review is underway, and blinded safety data will be included, but that's as far as the MAPLE data would go in contributing to an NDA.
Charles Duncan
analystUnderstood — that makes sense to me now. I appreciate you fielding my question.
Robert Blum
executiveYou're welcome.
Fady Malik
executiveThanks, Charles.
Robert Blum
executiveGood afternoon.
Analyst
analystGood afternoon, and thanks for fielding our questions. William speaking — I'm covering for Mayank today. If we think about a cardiac sarcomere modulator that falls outside the CMI category, what should we expect in terms of treatment effects for an obstructive HCM patient, or for that matter a non-obstructive one? Assuming hypercontractility sits at the root of the disease, would the results look the same, or would they diverge quite a bit? I'd really value your take on this.
Robert Blum
executiveHonestly, when it comes to something that isn't a CMI, I'm not even certain such an agent is out there, so speculating about the way it could address hypercontractility in HCM isn't something I can genuinely do. All right, as far as we can tell, every drug currently under investigation in clinical trials attaches to myosin and alters how myosin works, and the result is a reduction in the count of active cross-bridges, which in turn brings down contractility within the sarcomere. Sure, these agents might vary from one another when it comes to their exposure-response relationship or other distinctions, and obviously that could produce differing clinical profiles — but speculating about something that might not even be out there isn't something I can do. The other mechanism being looked at, I believe, is SGLT2 inhibitors in HCM, and in that case there's certainly some basis for thinking they could potentially show effectiveness. So look, there's evidence that SGLT2 inhibitors could be beneficial for HFpEF—that's heart failure with preserved ejection fraction. However, when it comes to HCM, specifically obstructive HCM, the real problem is the gradient itself and getting that gradient down. I'm just not convinced an SGLT2 would work all that well in those patients. It might be a different story with nHCM, since that condition looks a lot more like HFpEF and is a much nearer match to that group.
Mayank Mamtani
analystGot it. Thanks so much.
Robert Blum
executiveSure. Thank you.
Robert Blum
executiveHello, Jason.
Jason Butler
analystHey there, and thank you. Robert, hi, and I appreciate you fielding this. I have one more question regarding the omecamtiv trial. When considering the specific group of patients you're aiming for and the encouraging results you've already produced, what should our expectations be regarding the pace of recruitment? And can we draw any parallel to, well, the earlier trial when it comes to how quickly patients might be enrolled?
Robert Blum
executiveRight, so I'll turn to Fady and Stuart on this, but what we're discussing is a segment of the market where the event rate is particularly elevated and where the unmet need isn't being met by medications currently under investigation in other trials; therefore, we anticipate that this trial will be welcomed by investigators, who are already informing us that they have numerous patients fitting the criteria we've laid out; and let me also point out that the advanced heart failure patients from GALACTIC were featured in a publication. Mike Felker served as the lead author, and in that work you can observe significant morbidity, significant mortality, and the economic value in that context might be particularly significant. So Fady and Stuart, would you like to discuss enrolling that patient population in a trial?
Fady Malik
executiveStuart, please take it from here.
Stuart Kupfer
executiveSure thing. Thank you, Robert. As Robert mentioned, we're going after a population at high risk, patients whose needs aren't being met; and it's likewise the subset of patients in GALACTIC-HF where we saw, you know, a bigger degree of benefit from treatment; so the upside, naturally, is that a smaller trial becomes possible. We've said already that the intended population is roughly one-fourth the size of GALACTIC-HF, which again stems from the higher rate of events we anticipate. That means we can conduct a trial that's smaller, leaner, and hopefully quicker; and, you know, if you look at a contemporary trial like VICTORIA, then I think that serves as a solid comparison. That study took just a little over three years, from first patient in until study closure; and so, that's roughly how we're envisioning the study moving forward.
Robert Blum
executiveThank you, Jason.
Sean McCutcheon
analystHello, everyone. I appreciate the inquiry. Could you address why optimizing the dose matters, particularly regarding the 36-week non-obstructive cohort within FOREST? Considering the need to bring patients up to those greater dose levels, perhaps as a benefit you hold relative to a rival of your rival, how... In your view, how has this affected the KCCQ findings so far, and how might it do so going forward? And perhaps discuss the earlier KCCQ information and the way it has shaped the assumptions about statistical power for ACACIA. Thank you.
Robert Blum
executiveCorrect. To begin, I would point you toward the COACH manuscript that Fady mentioned during his prepared remarks. What we believe SEQUOIA highlighted was that, by adhering to the approach of aiming for the minimum effective dose and gradual escalation, every dose step may correspond to progressively greater plasma drug concentration and progressively greater efficacy. Consequently, we are particularly glad to observe that, as you know, we are not encountering discontinuations at any dose tied to low EF, nor reductions in titration at the lower doses. It is only at the greater doses that we sometimes observe a downward titration linked to an EF excursion, yet that comes alongside bigger magnitude effects on gradient. Thus, that represents the fundamental therapeutic hypothesis that we feel SEQUOIA resolved quite effectively. When it comes to applying this to nHCM, perhaps I will invite Fady and Stuart to address that point, please.
Fady Malik
executiveOkay, so my view is that with nHCM, the core idea is really about doing better on the hypercontractility that defines that condition. And it's a population where things vary a great deal. Certain patients are going to require a higher amount, others are going to require a lower amount. So it's really helpful to have a drug that's simple to titrate, and where we're able to use, if you will, the entire spectrum of doses, so we can get the largest possible treatment benefit for patients, while also avoiding, potentially, any worry about going too far, needing to reduce or halt the drug, and things like that. What we observed in the open-label extension and in FOREST, which I mentioned, and which has been published, plus the published results from REDWOOD, demonstrates a fairly striking impact on symptoms, KCCQ, and biomarkers. So when ACACIA was being designed, we factored in what we believed the effect size would be based on what we saw in the Phase II trial, REDWOOD, specifically Cohort 4 of REDWOOD. When SEQUOIA read out, that assisted us, if you will, in confirming that the placebo effect in that trial fell within the range we had anticipated, since Cohort 4 in REDWOOD lacked a placebo control; and so we incorporated all of that, and we believe we powered it appropriately with roughly 400 patients. Perhaps I'll pause here for the moment.
Robert Blum
executiveHey, Serge.
Serge Belanger
analystIt's Serge here — hello, Robert. Serge Belanger, joining from research today. Appreciate you taking our question. We were hoping to hear if you have any fresh perspectives or takeaways from the mavacamten rollout concerning the HCM market opportunity, and how you might be able to do better than their launch trajectory once your turn arrives. Thanks.
Robert Blum
executiveThanks for asking. First off, we want to stress that in our view, the Q2 sales for mavacamten answered quite a few of the remaining questions tied to the Q1 figures, and we believe they show precisely what ought to be anticipated from a launch of a drug that is serving the needs of particular patients at particular centers. We consider it a strong quarter-to-quarter increase. That said, as Andrew pointed out, we still believe more than 90% of eligible patients are not on a cardiac myosin inhibitor, and that figure will perhaps remain above 80% when we hopefully reach the market. We do believe that aficamten's next-in-class profile should, we hope, be expected to broaden the category so that more patients receive the benefit of cardiac myosin inhibition and more physicians prescribe it. Maybe I could ask Andrew to weigh in on what he's hearing in the marketplace and how aficamten's next-in-class profile may, we hope, meet market need.
Andrew Callos
executiveSure. When I consider how the launch is going to unfold, the key thing is obviously making sure cardiologists get educated, that we begin engaging them, and that utilization grows wider beyond centers of excellence and HCM experts, while also making certain patients are supported from both a patient support and service standpoint, along with affordability. So all of those pieces are where our attention is, to ensure the trajectory of this launch is, well, what we expect it to be. As for what the market is telling us, a second choice and alternative within the CMI space is definitely something we welcome. We absolutely believe it will grow the use of CMIs and keep the community involved.
Serge Belanger
analystGreat, thanks for that.
Rohan Mathur
analystHi, this is Rohan calling in from Oppenheimer. I appreciate you taking my question. Regarding CK-586 specifically, is there anything we've learned from the aficamten studies that could help shape how the Phase II trial for 586 is designed — particularly in terms of how safety and efficacy findings get assessed, keeping in mind that the HFpEF population has more severe disease? Thank you.
Robert Blum
executiveLet me just make sure I understand — your question has to do with aficamten in nHCM, in terms of what it tells us —
Robert Blum
executiveSo, CK-586 — that's for HFpEF, correct?
Rohan Mathur
analystThat is correct.
Robert Blum
executiveDid I get that right?
Rohan Mathur
analystYeah.
Robert Blum
executiveAll right. Fady, would you like to handle that, or should Stuart?
Fady Malik
executiveYeah, Stuart, do you want to go ahead and answer?
Stuart Kupfer
executiveOkay, so the brief response is that we have plenty to take away from this. A great deal has been gathered from the aficamten program — in non-obstructive HCM, and naturally in obstructive HCM as well. Yet it's obvious that the non-obstructive HCM group matters more when it comes to the HFpEF patients we're going after. The key emphasis, you know, sits on bettering diastolic function, and basically figuring out how much of a drop in cardiac contractility would bring about that improvement in diastolic function. And at this point we've gained some sense, some grasp of, say, the size of an ejection fraction reduction that could deliver possible upside where diastolic function is concerned, plus how that would carry over, naturally, to better symptoms and function. Alongside that, naturally, is what we've seen among the non-obstructive population: a highly favorable safety profile matching the proof of stronger efficacy. So we will definitely carry those findings into shaping, you know, refining the study design and aiming at the groups we believe might gain the most.
Rohan Mathur
analystThank you.
Stuart Kupfer
executiveThanks.
Robert Blum
executiveAppreciate it, operator, and I want to thank everyone for being with us today on this Q2 earnings call. This one carries particular weight given certain matters we've been discussing. With aficamten's progress, we're quite happy to have kicked off the rolling NDA submission, and we expect to wrap that up during this quarter, and in particular, following the meetings we've held with FDA, which we think shape our approach when it comes to risk mitigation and other items that the review will take into account. We're also very glad that the company's capital structure has been strengthened, and that we're deploying it effectively in a capital-efficient manner with respect to both omecamtiv and CK-586. We're eager to bring shareholders updates as we move our go-to-market strategies forward for aficamten and also with regard to the later-stage pipeline. Beyond that, we'll also highlight presentations taking place later this month at the European Society of Cardiology and look forward to talking with you following those. Operator, please go ahead and close out the call.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.